This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
References 1) Torre, L. A.; Bray, F.; Siegel, R. L.; Ferlay, J.; Lortet-Tieulent, J.; Jemal, A., Global
cancer statistics, 2012. CA Cancer J Clin 2015, 65 (2), 87-108.10.3322/caac.21262 2) Gillessen, S.; Attard, G.; Beer, T. M.; Beltran, H.; Bossi, A.; Bristow, R.; Carver, B.;
Castellano, D.; Chung, B. H.; Clarke, N.; Daugaard, G.; Davis, I. D.; de Bono, J.; Dos Reis, R. B.; Drake, C. G.; Eeles, R.; Efstathiou, E.; Evans, C. P.; Fanti, S.; Feng, F.; Fizazi, K.; Frydenberg, M.; Gleave, M.; Halabi, S.; Heidenreich, A.; Higano, C. S.; James, N.; Kantoff, P.; Kellokumpu-Lehtinen, P. L.; Khauli, R. B.; Kramer, G.; Logothetis, C.; Maluf, F.; Morgans, A. K.; Morris, M. J.; Mottet, N.; Murthy, V.; Oh, W.; Ost, P.; Padhani, A. R.; Parker, C.; Pritchard, C. C.; Roach, M.; Rubin, M. A.; Ryan, C.; Saad, F.; Sartor, O.; Scher, H.; Sella, A.; Shore, N.; Smith, M.; Soule, H.; Sternberg, C. N.; Suzuki, H.; Sweeney, C.; Sydes, M. R.; Tannock, I.; Tombal, B.; Valdagni, R.; Wiegel, T.; Omlin, A., Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol 2017.10.1016/j.eururo.2017.06.002
公益財団法人山口内分泌疾患研究振興財団 内分泌に関する最新情報 2018 年 4 月
9
3) Fujimura, T.; Takayama, K.; Takahashi, S.; Inoue, S., Estrogen and androgen blockade for advanced prostate cancer in the era of precision medicine. Cancers 2018, 10 (2).10.3390/cancers10020029
4) Huggins, C.; Hodges, C. V., Studies on prostatic cancer. I. The effect of castration,
of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972, 22 (4), 232-40
5) Obinata, D.; Takayama, K.; Takahashi, S.; Inoue, S., Crosstalk of the androgen
receptor with transcriptional collaborators: potential therapeutic targets for castration-resistant prostate cancer. Cancers 2017, 9 (3).10.3390/cancers9030022
6) McDevitt, M. A.; Glidewell-Kenney, C.; Jimenez, M. A.; Ahearn, P. C.; Weiss, J.;
Jameson, J. L.; Levine, J. E., New insights into the classical and non-classical actions of estrogen: evidence from estrogen receptor knock-out and knock-in mice. Mol Cell Endocrinol 2008, 290 (1-2), 24-30.10.1016/j.mce.2008.04.003
7) Takizawa, I.; Lawrence, M. G.; Balanathan, P.; Rebello, R.; Pearson, H. B.;
Garg, E.; Pedersen, J.; Pouliot, N.; Nadon, R.; Watt, M. J.; Taylor, R. A.; Humbert, P.; Topisirovic, I.; Larsson, O.; Risbridger, G. P.; Furic, L., Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget 2015, 6 (2), 604-16.10.18632/oncotarget.2820
8) Dey, P.; Jonsson, P.; Hartman, J.; Williams, C.; Strom, A.; Gustafsson, J. A., Estrogen
receptors beta1 and beta2 have opposing roles in regulating proliferation and bone metastasis genes in the prostate cancer cell line PC3. Mol Endocrinol 2012, 26 (12), 1991-2003.10.1210/me.2012.1227
Inoue, S.; Yanagisawa, J., Estrogen exhibits a biphasic effect on prostate tumor growth through the estrogen receptor beta-KLF5 pathway. Mol Cell Biol 2016, 36 (1), 144-56.10.1128/MCB.00625-15
11) Leung, Y. K.; Gao, Y.; Lau, K. M.; Zhang, X.; Ho, S. M., ICI 182,780-regulated gene
expression in DU145 prostate cancer cells is mediated by estrogen receptor-beta/NFkappaB crosstalk. Neoplasia 2006, 8 (4), 242-9.10.1593/neo.05853
12) Wu, W. F.; Maneix, L.; Insunza, J.; Nalvarte, I.; Antonson, P.; Kere, J.; Yu, N. Y.;
Tohonen, V.; Katayama, S.; Einarsdottir, E.; Krjutskov, K.; Dai, Y. B.; Huang, B.; Su, W.; Warner, M.; Gustafsson, J. A., Estrogen receptor beta, a regulator of androgen receptor signaling in the mouse ventral prostate. Proc Natl Acad Sci U S A 2017, 114 (19), E3816-e3822.10.1073/pnas.1702211114
公益財団法人山口内分泌疾患研究振興財団 内分泌に関する最新情報 2018 年 4 月
10
13) Gehrig, J.; Kaulfuss, S.; Jarry, H.; Bremmer, F.; Stettner, M.; Burfeind, P.; Thelen, P., Prospects of estrogen receptor beta activation in the treatment of castration-resistant prostate cancer. Oncotarget 2017, 8 (21), 34971-34979.10.18632/oncotarget.16496
14) Bianco, S.; Sailland, J.; Vanacker, J. M., ERRs and cancers: effects on metabolism
and on proliferation and migration capacities. The Journal of steroid biochemistry and molecular biology 2012, 130 (3-5), 180-5.10.1016/j.jsbmb.2011.03.014
15) Bianco, S.; Lanvin, O.; Tribollet, V.; Macari, C.; North, S.; Vanacker, J. M., Modulating
estrogen receptor-related receptor-alpha activity inhibits cell proliferation. The Journal of biological chemistry 2009, 284 (35), 23286-92.10.1074/jbc.M109.028191
16) Bernatchez, G.; Giroux, V.; Lassalle, T.; Carpentier, A. C.; Rivard, N.; Carrier, J. C.,
ERRalpha metabolic nuclear receptor controls growth of colon cancer cells. Carcinogenesis 2013, 34 (10), 2253-61.10.1093/carcin/bgt180
17) Wu, Y. M.; Chen, Z. J.; Liu, H.; Wei, W. D.; Lu, L. L.; Yang, X. L.; Liang, W. T.; Liu, T.;
Liu, H. L.; Du, J.; Wang, H. S., Inhibition of ERRalpha suppresses epithelial mesenchymal transition of triple negative breast cancer cells by directly targeting fibronectin. Oncotarget 2015, 6 (28), 25588-601.10.18632/oncotarget.4436
18) Zou, C.; Yu, S.; Xu, Z.; Wu, D.; Ng, C. F.; Yao, X.; Yew, D. T.; Vanacker, J. M.;
Chan, F. L., ERRalpha augments HIF-1 signalling by directly interacting with HIF-1alpha in normoxic and hypoxic prostate cancer cells. The Journal of pathology 2014, 233 (1), 61-73.10.1002/path.4329
Castronovo, V.; Follet, H.; Descotes, F.; Aubin, J. E.; Clezardin, P.; Bonnelye, E., Dual function of ERRalpha in breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. Cancer Res 2011, 71 (17), 5728-38.10.1158/0008-5472.can-11-1431
20) Dwyer, M. A.; Joseph, J. D.; Wade, H. E.; Eaton, M. L.; Kunder, R. S.; Kazmin, D.;
Chang, C. Y.; McDonnell, D. P., WNT11 expression is induced by estrogen-related receptor alpha and beta-catenin and acts in an autocrine manner to increase cancer cell migration. Cancer Res 2010, 70 (22), 9298-308.10.1158/0008-5472.can-10-0226
21) <ERRalpha bone meta Oncotarget 2017.pdf>. 22) Kroiss, A.; Vincent, S.; Decaussin-Petrucci, M.; Meugnier, E.; Viallet, J.; Ruffion, A.;
Chalmel, F.; Samarut, J.; Allioli, N., Androgen-regulated microRNA-135a decreases prostate cancer cell migration and invasion through downregulating ROCK1 and ROCK2. Oncogene 2015, 34 (22), 2846-55.10.1038/onc.2014.222
Perian, S.; Allioli, N.; Samarut, J.; Vanacker, J. M., miR-135a inhibits the invasion of cancer cells via suppression of ERRalpha. PLoS One 2016, 11 (5), e0156445.10.1371/journal.pone.0156445
24) Lonard, D. M.; Smith, C. L., Molecular perspectives on selective estrogen receptor
modulators (SERMs): progress in understanding their tissue-specific agonist and antagonist actions. Steroids 2002, 67 (1), 15-24
公益財団法人山口内分泌疾患研究振興財団 内分泌に関する最新情報 2018 年 4 月
11
25) Taneja, S. S.; Smith, M. R.; Dalton, J. T.; Raghow, S.; Barnette, G.; Steiner, M.; Veverka, K. A., Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. Expert opinion on investigational drugs 2006, 15 (3), 293-305.10.1517/13543784.15.3.293
26) Dutertre, M.; Smith, C. L., Molecular mechanisms of selective estrogen receptor
modulator (SERM) action. The Journal of pharmacology and experimental therapeutics 2000, 295 (2), 431-7
27) Raghow, S.; Hooshdaran, M. Z.; Katiyar, S.; Steiner, M. S., Toremifene prevents
prostate cancer in the transgenic adenocarcinoma of mouse prostate model. Cancer Res 2002, 62 (5), 1370-6
28)Hariri, W.; Sudha, T.; Bharali, D. J.; Cui, H.; Mousa, S. A., Nano-targeted
delivery of toremifene, an estrogen receptor-alpha blocker in prostate cancer. Pharmaceutical research 2015, 32 (8), 2764-74.10.1007/s11095-015-1662-x
S. B.; Vaughn, D. J., Phase II trial of toremifene in androgen-independent prostate cancer: a Penn cancer clinical trials group trial. American journal of clinical oncology 2001, 24 (3), 283-5
Bostwick, D.; Steiner, M., Toremifene for the prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia: results of a double-blind, placebo controlled, phase IIB clinical trial. J Urol 2006, 176 (3), 965-70; discussion 970-1.10.1016/j.juro.2006.04.011
31) Smith, M. R.; Malkowicz, S. B.; Chu, F.; Forrest, J.; Price, D.; Sieber, P.;
Barnette, K. G.; Rodriguez, D.; Steiner, M. S., Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008, 179 (1), 152-5.10.1016/j.juro.2007.08.137
32) Taneja, S. S.; Morton, R.; Barnette, G.; Sieber, P.; Hancock, M. L.; Steiner, M.,
Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013, 31 (5), 523-9.10.1200/jco.2012.41.7634
33) Smith, M. R.; Malkowicz, S. B.; Chu, F.; Forrest, J.; Sieber, P.; Barnette, K. G.;
Rodriquez, D.; Steiner, M. S., Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008, 26 (11), 1824-9.10.1200/jco.2007.13.5517
34) Draper, M. W.; Flowers, D. E.; Huster, W. J.; Neild, J. A.; Harper, K. D.; Arnaud, C.,
A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 1996, 11 (6), 835-42.10.1002/jbmr.5650110615
公益財団法人山口内分泌疾患研究振興財団 内分泌に関する最新情報 2018 年 4 月
12
35) Shazer, R. L.; Jain, A.; Galkin, A. V.; Cinman, N.; Nguyen, K. N.; Natale, R. B.; Gross, M.; Green, L.; Bender, L. I.; Holden, S.; Kaplan, L.; Agus, D. B., Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU international 2006, 97 (4), 691-7.10.1111/j.1464-410X.2006.05974.x
36) Ho, T. H.; Nunez-Nateras, R.; Hou, Y. X.; Bryce, A. H.; Northfelt, D. W.; Dueck, A. C.;
Wong, B.; Stanton, M. L.; Joseph, R. W.; Castle, E. P., A study of combination bicalutamide and raloxifene for patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2017, 15 (2), 196-202 e1.10.1016/j.clgc.2016.08.026
Escott, P.; Payne, V.; Trump, D. L., Phase II study of fulvestrant (Faslodex) in castration resistant prostate cancer. The Prostate 2008, 68 (13), 1461-6.10.1002/pros.20813
38) Yu, E. Y.; Getzenberg, R. H.; Coss, C. C.; Gittelman, M. M.; Keane, T.; Tutrone, R.;
Belkoff, L.; Given, R.; Bass, J.; Chu, F.; Gambla, M.; Gaylis, F.; Bailen, J.; Hancock, M. L.; Smith, J.; Dalton, J. T.; Steiner, M. S., Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol 2015, 67 (2), 334-41.10.1016/j.eururo.2014.06.011
Suzuki, M.; Fukuhara, H.; Nakagawa, T.; Inoue, S.; Homma, Y., Toremifene, a selective estrogen receptor modulator, significantly improved biochemical recurrence in bone metastatic prostate cancer: a randomized controlled phase II a trial. BMC Cancer 2015, 15, 836.10.1186/s12885-015-1871-z
40) Howell, A.; Osborne, C. K.; Morris, C.; Wakeling, A. E., ICI 182,780 (Faslodex):
development of a novel, "pure" antiestrogen. Cancer 2000, 89 (4), 817-25 41) Carlson, R. W.; Allred, D. C.; Anderson, B. O.; Burstein, H. J.; Edge, S. B.; Farrar,
W. B.; Forero, A.; Giordano, S. H.; Goldstein, L. J.; Gradishar, W. J.; Hayes, D. F.; Hudis, C. A.; Isakoff, S. J.; Ljung, B. M.; Mankoff, D. A.; Marcom, P. K.; Mayer, I. A.; McCormick, B.; Pierce, L. J.; Reed, E. C.; Smith, M. L.; Soliman, H.; Somlo, G.; Theriault, R. L.; Ward, J. H.; Wolff, A. C.; Zellars, R.; Kumar, R.; Shead, D. A., Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. Journal of the National Comprehensive Cancer Network : JNCCN 2012, 10 (7), 821-9
42) Rothschild, S. I., Targeted therapies in non-small cell lung cancer-beyond EGFR
and ALK. Cancers 2015, 7 (2), 930-49.10.3390/cancers7020816 43) Choudhury, A. D.; Eeles, R.; Freedland, S. J.; Isaacs, W. B.; Pomerantz, M. M.;
Schalken, J. A.; Tammela, T. L.; Visakorpi, T., The role of genetic markers in the management of prostate cancer. Eur Urol 2012, 62 (4), 577-87.10.1016/j.eururo. 2012.05.054
44) Markert, E. K.; Mizuno, H.; Vazquez, A.; Levine, A. J., Molecular classification of
prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A 2011, 108 (52), 21276-81.10.1073/pnas.1117029108
公益財団法人山口内分泌疾患研究振興財団 内分泌に関する最新情報 2018 年 4 月
13
45) Martens-Uzunova, E. S.; Jalava, S. E.; Dits, N. F.; van Leenders, G. J.; Moller, S.; Trapman, J.; Bangma, C. H.; Litman, T.; Visakorpi, T.; Jenster, G., Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2012, 31 (8), 978-91.10.1038/onc.2011.304
46) Cuzick, J.; Swanson, G. P.; Fisher, G.; Brothman, A. R.; Berney, D. M.; Reid, J. E.;
Mesher, D.; Speights, V. O.; Stankiewicz, E.; Foster, C. S.; Moller, H.; Scardino, P.; Warren, J. D.; Park, J.; Younus, A.; Flake, D. D., 2nd; Wagner, S.; Gutin, A.; Lanchbury, J. S.; Stone, S., Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. The Lancet. Oncology 2011, 12 (3), 245-55.10.1016/s1470-2045(10)70295-3
Ravindranath, L.; Osborn, D. J.; Rosner, I. L.; Dobi, A.; McLeod, D. G.; Sesterhenn, I. A.; Srivastava, S.; Cullen, J.; Petrovics, G., Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res 2008, 14 (3), 758-63.10.1158/1078-0432.ccr-07-1356
48) Nonn, L.; Vaishnav, A.; Gallagher, L.; Gann, P. H., mRNA and micro-RNA
expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials. Experimental and molecular pathology 2010, 88 (1), 45-51.10.1016/j.yexmp.2009.10.005
49) Rogerson, L.; Darby, S.; Jabbar, T.; Mathers, M. E.; Leung, H. Y.; Robson, C. N.;
Sahadevan, K.; O'Toole, K.; Gnanapragasam, V. J., Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU international 2008, 102 (3), 364-70.10.1111/j.1464-410X.2008.07627.x
50) Bancroft, E. K.; Page, E. C.; Castro, E.; Lilja, H.; Vickers, A.; Sjoberg, D.; Assel, M.;
Foster, C. S.; Mitchell, G.; Drew, K.; Maehle, L.; Axcrona, K.; Evans, D. G.; Bulman, B.; Eccles, D.; McBride, D.; van Asperen, C.; Vasen, H.; Kiemeney, L. A.; Ringelberg, J.; Cybulski, C.; Wokolorczyk, D.; Selkirk, C.; Hulick, P. J.; Bojesen, A.; Skytte, A. B.; Lam, J.; Taylor, L.; Oldenburg, R.; Cremers, R.; Verhaegh, G.; van Zelst-Stams, W. A.; Oosterwijk, J. C.; Blanco, I.; Salinas, M.; Cook, J.; Rosario, D. J.; Buys, S.; Conner, T.; Ausems, M. G.; Ong, K. R.; Hoffman, J.; Domchek, S.; Powers, J.; Teixeira, M. R.; Maia, S.; Foulkes, W. D.; Taherian, N.; Ruijs, M.; Helderman-van den Enden, A. T.; Izatt, L.; Davidson, R.; Adank, M. A.; Walker, L.; Schmutzler, R.; Tucker, K.; Kirk, J.; Hodgson, S.; Harris, M.; Douglas, F.; Lindeman, G. J.; Zgajnar, J.; Tischkowitz, M.; Clowes, V. E.; Susman, R.; Ramon y Cajal, T.; Patcher, N.; Gadea, N.; Spigelman, A.; van Os, T.; Liljegren, A.; Side, L.; Brewer, C.; Brady, A. F.; Donaldson, A.; Stefansdottir, V.; Friedman, E.; Chen-Shtoyerman, R.; Amor, D. J.; Copakova, L.; Barwell, J.; Giri, V. N.; Murthy, V.; Nicolai, N.; Teo, S. H.; Greenhalgh, L.; Strom, S.; Henderson, A.; McGrath, J.; Gallagher, D.; Aaronson, N.; Ardern-Jones, A.; Bangma, C.; Dearnaley, D.; Costello, P.; Eyfjord, J.; Rothwell, J.; Falconer, A.; Gronberg, H.; Hamdy, F. C.; Johannsson, O.; Khoo, V.; Kote-Jarai, Z.; Lubinski, J.; Axcrona, U.; Melia, J.; McKinley, J.; Mitra, A. V.; Moynihan, C.; Rennert, G.; Suri, M.; Wilson, P.; Killick, E.; Moss, S.; Eeles, R. A., Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. Eur Urol 2014, 66 (3), 489-99.10.1016/j.eururo.2014.01.003
公益財団法人山口内分泌疾患研究振興財団 内分泌に関する最新情報 2018 年 4 月
14
51) Na, R.; Zheng, S. L.; Han, M.; Yu, H.; Jiang, D.; Shah, S.; Ewing, C. M.; Zhang, L.; Novakovic, K.; Petkewicz, J.; Gulukota, K.; Helseth, D. L., Jr.; Quinn, M.; Humphries, E.; Wiley, K. E.; Isaacs, S. D.; Wu, Y.; Liu, X.; Zhang, N.; Wang, C. H.; Khandekar, J.; Hulick, P. J.; Shevrin, D. H.; Cooney, K. A.; Shen, Z.; Partin, A. W.; Carter, H. B.; Carducci, M. A.; Eisenberger, M. A.; Denmeade, S. R.; McGuire, M.; Walsh, P. C.; Helfand, B. T.; Brendler, C. B.; Ding, Q.; Xu, J.; Isaacs, W. B., Germline Mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death. Eur Urol 2017, 71 (5), 740-747.10.1016/j.eururo.2016.11.033
52) Rubicz, R.; Zhao, S.; Wright, J. L.; Coleman, I.; Grasso, C.; Geybels, M. S.;
Leonardson, A.; Kolb, S.; April, C.; Bibikova, M.; Troyer, D.; Lance, R.; Lin, D. W.; Ostrander, E. A.; Nelson, P. S.; Fan, J. B.; Feng, Z.; Stanford, J. L., Gene expression panel predicts metastatic-lethal prostate cancer outcomes in men diagnosed with clinically localized prostate cancer. Molecular oncology 2017, 11 (2), 140-150.10.1002/1878-0261.12014
Ouchi, Y.; Inoue, S., FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells. Biochem Biophys Res Commun 2008, 374 (2), 388-93.10.1016/j.bbrc.2008.07.056
Ikeda, K.; Horie-Inoue, K.; Homma, Y.; Ouchi, Y.; Takahashi, S.; Inoue, S., Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. International journal of cancer 2012, 130 (5), 1021-8.10.1002/ijc.26043
56) Takayama, K.; Inoue, S., Transcriptional network of androgen receptor in prostate
cancer progression. International journal of urology : official journal of the Japanese Urological Association 2013, 20 (8), 756-68.10.1111/iju.12146
Yamada, Y.; Kumagai, J.; Kume, H.; Ouchi, Y.; Inoue, S.; Homma, Y., Expression of androgen and estrogen signaling components and stem cell markers to predict cancer progression and cancer-specific survival in patients with metastatic prostate cancer. Clin Cancer Res 2014, 20 (17), 4625-35.10.1158/1078-0432.CCR-13-1105